Compositions Comprising Gelatin, Gelatin Films, and Capsules

Surfactants in gelatin films address the challenge of achieving enteric release profiles in gelatin capsules by ensuring slow dissolution at low pH and fast dissolution at neutral pH, improving processing efficiency and safety without additional coatings.

JP2024542307APending Publication Date: 2024-11-14TESSENDERLO GROUP NV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024523251
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-20
Filing Date
2022-10-20
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing gelatin capsules face challenges in achieving a slow dissolution rate at low pH and fast dissolution rate at neutral pH without the need for complex enteric coatings, which can lead to processing issues, coating defects, and safety hazards.

Method used

Incorporating effective amounts of surfactants, such as anionic, cationic, nonionic, or amphoteric surfactants, into gelatin films to achieve a slow dissolution rate at low pH and a fast dissolution rate at neutral pH, eliminating the need for additional polymer coatings.

Benefits of technology

The surfactant-enhanced gelatin films exhibit the desired enteric release profile, providing delayed release at low pH and rapid release at neutral pH, enhancing processing efficiency and safety while maintaining film integrity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542307000001
    Figure 2024542307000001
  • Figure 2024542307000002
    Figure 2024542307000002
  • Figure 2024542307000003
    Figure 2024542307000003
Patent Text Reader

Abstract

The present invention provides a film comprising gelatin as a film former and a surfactant in an amount effective to provide a delayed dissolution rate at low pH compared to the dissolution rate at neutral pH. In particular, the effective amount of surfactant is an amount that provides a dissolution rate such that not more than 50% of the film dissolves within 120 minutes at 37° C. and a pH of about 1, and more than 50% of the film dissolves in 45 minutes at pH 6.8 and 37° C. Surfactants include anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants. A preferred film comprises gelatin and about 8% by weight or more of C8-C9 surfactant on a dry weight basis. 24 and an anionic surfactant having an alkyl chain.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions comprising gelatin and a surfactant, more particularly to films comprising gelatin as a film former and a surfactant, and to capsules comprising such films. The present invention also relates to methods for preparing the films and to the use of the surfactant in the gelatin compositions, films, and capsules.

[0002] The compositions, films, and capsules of the present invention exhibit a slow dissolution rate at low pH and a fast dissolution rate at neutral pH. Thus, the capsules of the present invention with active ingredients provide a delayed release profile at low pH and a fast release profile at neutral pH. [Background technology]

[0003] Gelatin is a translucent, tasteless, water-soluble protein derived from boiled animal tissue. It is commonly used as an excipient for pharmaceutical and food supplement applications, for example to make hard or soft gelatin capsules.

[0004] Hard capsules are generally filled with solid products such as powders, pellets, granules, or mini-tablets, e.g., solids that are unpleasant tasting or irritating on direct contact with the gastrointestinal tract. Hard capsules consist of two halves (the capsule body and the capsule cap) that fit together.

[0005] Soft capsules (also called softgels) are generally useful for drug formulations containing liquids, oils, pastes, or suspensions. The advantages of soft capsules are product stability (prevention of oxidative degradation), ease of swallowing, and good dose uniformity for low dose drugs (because liquid flow and homogeneity is more precise than powder flow).

[0006] The melting point of gelatin is close to body temperature, and gelatin dissolves more easily in acidic environment than in neutral environment. Therefore, gelatin capsules are easily digested in the stomach, and therefore their contents are also released in the stomach. For drugs or dietary supplements that are sensitive to the acidic conditions of the stomach (e.g., enzymes, peptides, or proton pump inhibitors), irritate the gastric mucosa (e.g., nonsteroidal anti-inflammatory drugs, NSAIDs), and / or need to be delivered to the intestine (e.g., colon) to obtain local effects, it is preferable for the capsule to reach the intestine before releasing its contents. It may also be preferable for the capsule to reach the intestine before releasing its contents to minimize burping and reflux of stomach acid.

[0007] To achieve such a specific dissolution profile, there are several solutions, such as delayed release capsules, especially so-called "enteric capsules". Delayed release capsules are designed to release their contents, generally gradually, some time after administration, which can be advantageous. In some cases, after this period, the release can be rapid. Enteric capsules are a subgroup of delayed release capsules. Enteric capsules release little or none of their contents at low pH (such as the stomach), but release most of their contents at higher pH (such as the intestine).

[0008] To achieve such enteric behavior in gelatin capsules, such capsules are generally coated with a so-called enteric coating, which is a polymer barrier that protects the gelatin capsule from premature disintegration at low pH. The coating is typically pH-activated, remaining intact at low pH but dissolving readily as the pH of the intestine increases.

[0009] More specifically, enteric behavior is obtained if the enteric dosage form does not dissolve or disintegrate at gastric acidity over a specific time (usually 2 hours in 0.1 M hydrochloric acid at 37° C.). Furthermore, the enteric dosage form must release their contents in a simulated intestinal environment (e.g., in a buffer with a pH value of about 6.8 within a certain period of time). Detailed evaluation techniques are described in national and international pharmacopoeias such as the European Pharmacopoeia.

[0010] For example, examples of enteric coatings for capsules are described in Chinese Patent Application Publication Nos. 103800303A, 104434870A, US Pat. No. 5,330,759A, European Patent Application Publication Nos. 3,090,637A and 2,255,794A.

[0011] Providing such a protective layer requires an extra and rather complicated process step in the manufacturing process of the capsule, which may result in longer processing times, more complicated processes, and yield losses, and furthermore, the added process steps may result in sealing problems.

[0012] Furthermore, many process parameters can affect the coating process and the quality of the coating. This can lead to undesirable variations in peeling behavior due to coating variability and defects such as chipping, cracking, and peeling. In addition, aqueous solvents used during the coating process can affect drying time and microbiological stability, while organic solvents can pose safety and environmental hazards as well as solvent residue issues. Some acid-resistant coatings, such as Eudragit, may not be suitable for direct coating of gelatin capsules due to poor film adhesion and brittleness of the film formed. Capsule opacity can be affected by the coating, resulting in a less attractive capsule.

[0013] Additional difficulties can arise when coating soft gelatin capsules due to their smooth, non-absorbent surface, flexibility, and elasticity.

[0014] It is an object of the present invention to provide a film, or a capsule containing a film, that exhibits a slow dissolution rate at low pH and a fast dissolution rate at neutral pH.

[0015] It is a further object of the present invention to provide a capsule having a desired enteric release profile without the need for a coating.

[0016] It is a further object of the present invention to provide a more efficient method for preparing films that exhibit a relatively slow dissolution rate at low pH while exhibiting a fast dissolution rate at neutral pH. Summary of the Invention

[0017] One or more of the above objects are achieved by the present invention which provides a composition, preferably a homogeneous composition, more preferably a homogeneous solid or liquid composition, even more preferably a homogeneous solid composition, comprising gelatin and a surfactant, particularly gelatin as a film former and a surfactant, preferably a film comprising an effective amount of a surfactant, to provide a slow dissolution rate at low pH in an aqueous medium compared to a fast dissolution rate at neutral pH in the aqueous medium.

[0018] Preferably, the dissolution rate is - no more than 50% of the film dissolves within 120 minutes at 37°C and a pH of about 1, more specifically in 0.1M aqueous HCl; - such that more than 50% of the film dissolves within 45 minutes at pH 6.8, 37°C, more specifically in 0.05M sodium phosphate buffer.

[0019] The dissolution rate of the film is preferably such as to provide a capsule with delayed release in the stomach, more preferably a capsule with enteric behavior (less than 10% release in the stomach in 2 hours and providing complete release in the intestine).

[0020] Depending on the surfactant, the amount needed or useful may vary, but generally the amount of surfactant is about 3% by weight or more, preferably about 5% by weight or more, and may be 6% by weight or more, 7% by weight or more, 8% by weight or more, 9% by weight or more, 10% by weight or more. Those skilled in the art can easily evaluate the amount needed for suitable delayed dissolution at low pH.

[0021] Generally, the amount of surfactant will be no more than about 30% by weight, preferably no more than about 20% by weight, and even more preferably no more than about 15% by weight.

[0022] Weight percentages are defined in this application as being relative to a dry gelatin film (or capsule shell) having a moisture content of 12% by weight, unless otherwise stated.

[0023] Unexpectedly, the incorporation of an effective amount of a surfactant into the film results in a delayed dissolution rate at low pH, but a rapid dissolution rate at neutral pH, and thus capsules containing the film exhibit the desired delayed release behavior.

[0024] Suitable surfactants include anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

[0025] In one preferred embodiment, the surfactant is an anionic surfactant.

[0026] In another preferred embodiment, the surfactant is a cationic surfactant.

[0027] In another preferred embodiment, the surfactant is a non-ionic surfactant.

[0028] In another preferred embodiment, the surfactant is an amphoteric surfactant.

[0029] Additionally, capsules are provided in which the films of the present invention encapsulate a fill material, such fill material preferably comprising a dietary supplement or an active pharmaceutical ingredient.

[0030] 1. A method for preparing a film comprising the steps of: (a) preparing an aqueous gelatin solution containing 20% ​​by weight or more and 50% by weight or less of gelatin and 3% by weight or more of a surfactant; (b) drying to form a film; There is further provided a method wherein the film exhibits a slow dissolution rate at pH 1 and a fast dissolution rate at neutral pH.

[0031] The method of the present invention does not require an additional coating step with a polymer to provide enteric behavior, resulting in a more efficient process.

[0032] In a particularly preferred embodiment, the present invention relates to a gelatin-based gelatin composition comprising a C8-C 24 and about 8% by weight or more of an anionic surfactant having an alkyl chain.

[0033] A surfactant in the gelatin film, preferably in an amount of about 8% by weight or more, C8-C10, to achieve a slow dissolution rate at low pH but have a fast dissolution rate at neutral pH. 24 There is further provided the use of an anionic surfactant having an alkyl chain.

[0034] European Patent Application Publication No. EP1210936A discloses a process for the preparation of gelatin capsules that reduces static generation and improves lubricity of the capsule film surface while using less than 1% by weight of surfactants. The capsules are not disclosed to exhibit an enteric or delayed dissolution profile in acidic environments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] The films of the present invention comprise gelatin as a film former and a surfactant in an amount effective to provide a delayed dissolution rate of the gelatin film at low pH compared to a fast dissolution rate at neutral pH.

[0036] gelatin Preferably, the film comprises gelatin in an amount of from about 30% to about 87% by weight, and more preferably from about 35% to about 80% by weight, on a dry weight basis.

[0037] Amounts are given by weight for films having a moisture content of 12% by weight unless otherwise stated.

[0038] Gelatin can include Type B gelatin (alkali processed) or Type A gelatin (acid processed).

[0039] Gelatine may be derived from any suitable source such as bones and / or hides / rinds and / or cartilage of various animals such as pigs, beef cattle, poultry, goats, donkeys, etc., or fish scales and / or skins. Preferably, the gelatine is derived from bones and / or hides of pigs and / or beef cattle.

[0040] In a preferred embodiment, the gelatin is preferably of the "high bloom" type, more preferably having a bloom strength of about 200 to about 280 g bloom. Preferably, the viscosity is about 4 to about 5 mPa s.

[0041] Bloom strength is measured according to the Bloom test, which is commonly known and described in the GME monograph (Version 15, October 2020). Viscosity is also determined according to this GME monograph. For a 6.67% solution of gelatin, the flow time of 100 ml through a standard pipette is measured at 60 °C and the dynamic viscosity is calculated.

[0042] Weight percentage values ​​given herein, when referring to a dry basis, are measured at 12% moisture by weight.

[0043] The high bloom type is preferably used in hard capsules. The gelatin type for hard capsules is often type B, but type A hard capsules also exist.

[0044] In another preferred embodiment, the gelatin is preferably of the "medium bloom" type, more preferably of about 120 to about 220 g bloom. Preferably, the viscosity is about 2 to about 4 mPa s.

[0045] The medium bloom type is preferably used in softgel capsules, which are often made of type A gelatin, although type B gelatin soft capsules are also common.

[0046] Surfactants In one preferred embodiment, the surfactant is an anionic surfactant. Suitable anionic surfactants include sodium lauryl sulfate (SLS, sodium dodecyl sulfate), sodium lauryl ether sulfate, ammonium lauryl sulfate, ammonium lauryl ether sulfate, sodium stearate, magnesium stearate, calcium stearate, sodium stearyl fumarate, calcium stearyl fumarate, sodium stearoyl-2-lactylate, calcium stearoyl-2-lactylate, dioctyl sodium sulfosuccinate (sodium docusate), and sodium cetearyl sulfate.

[0047] In a more preferred embodiment, the surfactant is a cationic surfactant. Suitable cationic surfactants include quaternary ammonium compounds such as cetrimonium bromide and cetylpyridinium chloride.

[0048] In a further preferred embodiment, the surfactant is a non-ionic surfactant. Suitable non-ionic surfactants include polyoxyethylene alkyl ethers (macrogols), such as macrogol cetostearyl ether, macrogol lauryl ether, macrogol oleyl ether, and macrogol stearyl ether; sorbitan esters, such as sorbitan monostearate (E491), sorbitan tristearate (E492), sorbitan monolaurate (E493), sorbitan monooleate (E494), sorbitan monopalmitate (E495), and sorbitan trioleate (E496); polysorbate 20 (E432), polysorbate 40 (E434), polysorbate 60 (E435), polysorbate 65 (E436), and polysorbate 8. Polyoxyethylene sorbitan fatty acid esters (polysorbates), such as polyoxyethylene sorbitan 0 (E433), polyoxyl 8 stearate (E430), polyoxyl 40 stearate (E431); polyoxyethylene castor oil derivatives, such as sucrose esters, for example partial polyglycerol esters of polycondensed fatty acids of castor oil (E498); sucrose esters of fatty acids (E473); glucose esters and derivatives, glycerol esters, such as glyceryl monooleate; ethoxylated alkylphenols, ethoxylated fatty amines, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty acids, monoglycerides and derivatives, propoxylated and ethoxylated fatty acids, ethylene oxide (ethylene ethoxylated alcohols such as block copolymers of ethylene oxide (EO) and propylene oxide (PO), silicone-based surfactants, and mixtures of organosilicon surfactants with nonionic or ionic surfactants; copolymers of polysaccharides, acrylamide and acrylic acid; and acetylenic diol derivatives or tristyrylphenols, ethoxylated sorbitan esters.

[0049] Further suitable nonionic surfactants include esters of mono- and diglycerides (E472), such as acetates of mono- and diglycerides (E472a), lactates of mono- and diglycerides (E472b), citric acid esters of mono- and diglycerides (E472c) (also known as CITREM and commercially available), tartaric acid esters of mono- and diglycerides (E472d), diacetyl tartaric acid esters of mono- and diglycerides (E472e) (also known as DATEM and commercially available), and mixed esters (acetates and tartaric acid esters) of mono- and diglycerides (E472f). Preferred nonionic surfactants of this type include citrates of mono- and diglycerides (E472c) and diacetyl tartaric acid esters of mono- and diglycerides (E472e). The amount of nonionic surfactant in the film is preferably 3% by weight or more, preferably 5% by weight or more, based on dry weight. The amount of non-ionic surfactant in the film is preferably 30% by weight or less, more preferably 20% by weight or less, on a dry weight basis.

[0050] In a further preferred embodiment, the surfactant is an amphoteric surfactant. Suitable amphoteric surfactants include lecithin (E322) and lecithin derivatives; and imidazoline and imidazoline derivatives; triethanolamine oleate; and betaines such as cocamidopropyl betaine.

[0051] Particularly preferred films of the present invention comprise gelatin and C8-C 24 At least one anionic surfactant having an alkyl chain. Preferably, the C8 to C 24 The amount of the anionic surfactant having an alkyl chain is 40% by weight or less, more preferably 30% by weight or less.

[0052] Particularly preferred anionic surfactants are C8-C 24 and an anionic group (hereinafter, also referred to as "long-chain anionic surfactant").

[0053] Preferably, the anionic group of the long chain anionic surfactant is a sulfate, sulfonate, phosphate, phosphonate, or carboxylate group. More preferably, the anionic group is a strong acid group such as a sulfate or sulfonate group.

[0054] The long chain alkyl groups can be straight or branched.

[0055] Preferably, the long chain anionic surfactant comprises an ether or ester group.

[0056] The molecular weight of the long-chain anionic surfactant is preferably about 250 g / mol to about 600 g / mol, more preferably about 300 g / mol to about 400 g / mol.

[0057] Preferably, the long chain anionic surfactant is selected from the group consisting of sodium lauryl sulfate (SLS), sodium lauryl ether sulfate, ammonium lauryl sulfate, ammonium lauryl ether sulfate, sodium stearate, magnesium stearate, calcium stearate, sodium stearyl fumarate, calcium stearyl fumarate, sodium stearoyl-2-lactylate, calcium stearoyl-2-lactylate, dioctyl sodium sulfosuccinate (sodium docusate), sodium cetearyl sulfate.

[0058] More preferably, the long chain anionic surfactant is selected from the group consisting of sodium lauryl sulfate (SLS) and sodium lauryl ether sulfate, even more preferably sodium lauryl sulfate (SLS).

[0059] Sodium lauryl sulfate is widely used in cosmetics and non-parenteral pharmaceutical preparations, i.e. oral and topical applications. It is listed as GRAS and is included in the FDA Inactive Ingredients Guide (dental preparations; oral capsules, suspensions, and tablets; topical and vaginal preparations). It is included in non-parenteral medicines licensed in the UK and on the Canadian List of Acceptable Non-Medicinal Ingredients.

[0060] Like sodium lauryl sulfate, sodium cetyl sulfate and sodium stearyl sulfate are fatty acid sulfates. Sodium cetearyl sulfate is a mixture of sodium cetyl sulfate and sodium stearyl sulfate. They are known pharmaceutical excipients.

[0061] Sodium lauryl ether sulfate (SLES), also known as sodium laureth sulfate, is a fatty acid sulfate that contains an ethoxyl group in the fatty acid chain. It has the formula:

[0062] [ka]

[0063] Ammonium lauryl ether sulfate has ammonium as the cation instead of sodium. Both sodium lauryl ether sulfate and ammonium lauryl ether sulfate are known pharmaceutical excipients.

[0064] Sodium, potassium and calcium salts of fatty acids are approved as food additives in the EU under E number E470a, and magnesium salts of fatty acids under E number E470b. These include salts of stearic acid, lauric acid, etc.

[0065] Dioctyl sodium sulfosuccinate, also known as docusate sodium and having the E number E480, is a known pharmaceutical excipient. Docusate sodium has the following formula:

[0066] [ka]

[0067] Sodium stearoyl-2-lactylate and calcium stearoyl-2-lactylate are approved as food additives in the EU under the E numbers E481 and E482, respectively, and have the following formula:

[0068] [ka]

[0069] Sodium stearyl fumarate and calcium stearyl fumarate are known under the E numbers E485 and E486 respectively and have the following formula:

[0070] [ka]

[0071] Plasticizers and other ingredients Preferably, if a softgel is intended, the film contains a plasticizer, which can be used to modify the physical properties of the film, making the soft capsule gelatin film elastic and flexible.

[0072] Preferably, the softgel film comprises a plasticizer in an amount of from about 10% to about 40% by weight, more preferably from about 15% to about 30% by weight.

[0073] Preferably, the plasticizer is selected from the group consisting of glycerol, propylene glycol, polyethylene glycol, sugar alcohols having 3 to 6 carbon atoms (such as sorbitol and mannitol), organic esters such as triethyl citrate and diethyl phthalate, and combinations thereof. More preferably, the plasticizer is selected from the group consisting of glycerol, sorbitol, polyethylene glycol, and combinations thereof. Even more preferably, the plasticizer comprises glycerol.

[0074] In a further preferred embodiment, the film further comprises an acid, preferably a weak acid, such as citric acid, lactic acid, glycolic acid, or hydrochloric acid. More preferably, the film comprises citric acid or lactic acid.

[0075] The film may further include colorants such as synthetic dyes, such as azo or non-azo dyes, or natural dyes. The film may further include an opacifier, such as TiO2, which allows for the production of an opaque shell that prevents photodegradation of the photosensitive fill material.

[0076] Films and capsules The films and capsules containing the films exhibit a delayed (relatively slow) dissolution rate at low pH and a fast dissolution rate at neutral pH, whereby the capsules containing the active compound exhibit a delayed release at low pH but dissolve rapidly at neutral pH, thereby providing a complete release of the active compound at such neutral pH.

[0077] Preferably, no more than 50% of the film dissolves within 120 minutes at 37° C. and a pH of about 1, more preferably no more than 40%, even more preferably no more than 30%, and even more preferably no more than 20%. For example, a 0.1 M hydrochloric acid solution can be used to carry out this test.

[0078] Preferably, 50% or more of the film dissolves within 45 minutes at 37° C. and a pH of about 6.8, more preferably 70% or more, even more preferably 80% or more, and even more preferably 90% or more. A buffer solution, such as 0.05 M sodium phosphate buffer at pH 6.8, can be used to carry out this test.

[0079] For simple delayed release formulations, dissolution of 80% or less in the first 60 minutes at 37° C. and a pH of about 1 is still commercially interesting. Thus, preferably, less than 80%, more preferably less than 70%, and even more preferably less than 60% of the film dissolves within 60 minutes at 37° C. and a pH of about 1. Preferably, less than 80%, more preferably less than 70%, and even more preferably less than 60% of the film dissolves within 120 minutes at 37° C. and a pH of about 1. Preferably, 80% or more, more preferably 90% or more of the film dissolves within 45 minutes at 37° C. and a pH of about 6.8.

[0080] Film thickness did not appear to significantly affect the dissolution rate. Thus, dissolution tests can be performed using films typically suitable for, for example, hard or soft capsules.

[0081] Preferably, where necessary or useful, dissolution testing for films suitable as soft capsules is performed on 1 mm films, whereas testing for films suitable for hard capsules is preferably performed on 0.1 mm films.

[0082] More preferably, the capsules containing the film exhibit enteric behavior as defined in accordance with the United States Pharmacopeia (USP). The USP requires an acid step of 1 hour duration, the medium containing 0.084M HCl, 0.034M NaCl, and 0.32% w / v pepsin. During this step, less than 10% of the active ingredient may be in solution. Additionally, a buffer step of pH 6.8 is required, the medium containing 0.05M phosphate buffer, 0.05M K + , 0.022M Na +, gastric enzymes and has an ionic strength of 0.094 M. After 45 minutes, greater than 85% of the active ingredient should be in solution.

[0083] More preferably, the capsules containing the film exhibit enteric behavior as defined in accordance with the European Pharmacopoeia (Ph.Eur.). Ph.Eur. requires a 2 hour acid step with 0.1M HCl medium, during which the active ingredient should not be in solution. The pH 6.8 buffer step comprises a 0.154M buffer with an ionic strength of 0.463M. The counter ions are Na + After 45 minutes, greater than 85% of the active ingredient should be in solution.

[0084] Even more preferably, the capsule containing the film passes the disintegration test defined in the European Pharmacopoeia, meaning that no defects should be observed in the capsule during the acid stage. The film should disintegrate during the second stage.

[0085] In one preferred embodiment, the film forms a hard capsule shell, which includes a capsule cap and a capsule body. Hard capsules are preferred for administering solid products. The hard capsule shell preferably comprises type B gelatin (alkali processed), but may also comprise type A gelatin (acid processed). Thus, in a preferred embodiment, the composition of the present invention is a hard capsule shell, which comprises a capsule cap and a capsule body.

[0086] Preferably, the hard capsule shell comprises a "high bloom" type gelatin, more preferably gelatin having a bloom strength of about 200 to about 280 g bloom. The gelatin preferably has a viscosity of about 4 to about 5 mPa s.

[0087] Preferably, the film forms a soft capsule shell. Soft gelatin capsules generally contain type B gelatin (alkali-treated), but may also contain type A gelatin (acid-treated). The gelatin is preferably of the "medium bloom" type, more preferably having a bloom strength of about 120 to about 220 g bloom. The gelatin preferably has a viscosity of about 2 to about 4 mPa s. Thus, in a preferred embodiment, the composition of the present invention is a soft capsule shell.

[0088] The film may have a thickness of 0.02 to 2 mm, and preferably has a thickness of 0.05 to 1.5 mm.

[0089] Typically, hard capsules contain a gelatin film of 0.05 to 0.15 mm, and soft capsules have a film thickness of 0.5 to 1.2 mm. Films for other purposes generally have a thickness in this range. Such thicknesses are particularly preferred for the films according to the invention.

[0090] The invention further provides a capsule in which the film of the invention encapsulates a fill material, typically an active ingredient. The fill material preferably comprises an active ingredient, such as a dietary supplement or an active pharmaceutical ingredient.

[0091] In one preferred embodiment, the capsule is a hard capsule, which may contain liquid or solid ingredients, preferably solid ingredients such as powders, pellets, granules, or mini-tablets.

[0092] In another preferred embodiment, the capsule is a soft capsule. The soft capsule preferably contains a liquid, oil, paste, emulsion or suspension.

[0093] process The present invention provides a method of preparing a film, the method comprising the steps of: (a) preparing an aqueous gelatin solution containing at least 20% and not more than 50% by weight gelatin and an effective amount of a surfactant to achieve a slow dissolution rate at low pH but have a fast dissolution rate at neutral pH; and (b) forming a film.

[0094] In a particularly preferred embodiment, the solution contains 6% by weight or more of C8-C 24 This includes anionic surfactants having alkyl chains.

[0095] The aqueous gelatin solution is prepared by dissolving gelatin and an anionic surfactant in water.

[0096] Preferably, the water is deionized water.

[0097] Preferably, the aqueous gelatin solution has a pH of about 3 to about 6.

[0098] When preparing soft gelatin capsules, a plasticizer is preferably added in an amount of about 10 to about 25% by weight of the solution.

[0099] In one embodiment, an acid is added. If an acid is used, the acid is citric acid or lactic acid, more preferably lactic acid. The acid can, among other things, allow the aqueous gelatin solution to reach the desired pH.

[0100] Preferably, dissolution of the gelatin and anionic surfactant is carried out under constant stirring.

[0101] Preferably, the dissolution of gelatin and anionic surfactant is carried out at a temperature of about 50°C to about 75°C.

[0102] Preferably, the dissolving and heating are carried out until the gelatin is dissolved, and more preferably, the dissolving and heating are carried out for about 10 minutes to about 30 minutes.

[0103] Preferably, the solution is filtered to remove solid contaminants that may cause defects in the film. More preferably, the solution is filtered through a mesh of 6 to 20 mesh (3.3 mm to 0.8 mm screen).

[0104] Preferably, the solution is degassed under reduced pressure, which reduces the occurrence of air bubbles that can cause defects in the film.

[0105] Preferably, step (b) comprises: (i) forming a film on the capsule cap and / or capsule body; and (ii) drying the capsule cap and / or capsule body to obtain the capsule body or capsule cap of the present invention.

[0106] The formation of the capsule cap and / or capsule body can be carried out according to any method known in the art. Generally, this is done by immersing a pair of standardized steel pins (body and cap) arranged in a row on a metal bar into an aqueous gelatin solution. After the gelatin solution is absorbed on the surface of the pins, the bar containing the pins is removed and rotated several times to distribute the solution evenly around the pins, forming the capsule cap and / or capsule body. The capsule cap and capsule body are then passed through several drying steps to achieve the desired moisture content and obtain the capsule body or capsule cap of the present invention.

[0107] In one preferred embodiment of the invention, the process of step (b) comprises: (i) forming the film into a capsule cap and / or capsule body; (ii) drying the capsule cap and / or capsule body.

[0108] In another preferred embodiment of the present invention, the process of step (b) comprises: (i) encapsulating a fill material containing a dietary supplement or an active pharmaceutical ingredient within a film to form a soft capsule; (ii) drying the soft capsule.

[0109] The encapsulation process can be carried out using methods known in the art such as the plate process, the rotary die process, the reciprocating die process, the acogel process, the seamless process, and the like.

[0110] The present invention further relates to the use of an effective amount of a surfactant in a gelatin-based film to provide a slow dissolution rate at low pH compared to a fast dissolution rate at neutral pH.

[0111] Preferably, the amount of surfactant is such that it provides a dissolution rate such that no more than 50% of a 1 mm film dissolves within 120 minutes at 37° C. and a pH of about 1, but greater than 50% at pH 6.8 in 45 minutes or less.

[0112] The present invention further relates to the use of an effective amount of a surfactant in a gelatin-based film to provide a capsule with delayed release behavior and preferably enteric behavior. EXAMPLES

[0113] For the dissolution tests the following amounts were used:

[0114] [Table 1]

[0115] Examples 1-2, Comparative Examples A-B Gelatin film preparation The gelatin used in the examples is acid-treated bone gelatin. It has a bloom strength of 180 g bloom and a viscosity of 2.5 mPa s. Measurements were made according to GME version number 15 of October 2020.

[0116] Gelatin, glycerol and sodium lauryl sulfate were dissolved in deionized water according to Table 1 and heated to 70° C. in an ultrasonic bath for 2 hours.

[0117] Glycerol is used as an 86% aqueous solution. Amounts on a dry basis are calculated based on 100% glycerol.

[0118] Dry basis amounts are for the dry film.

[0119] [Table 2]

[0120] The resulting mixture was cooled to room temperature (22° C.), cast into a film, and allowed to solidify. The gelatin film was dried until it reached a moisture content of 12%. The thickness dimensions of the prepared films are provided below.

[0121] [Table 3]

[0122] Dissolution Test The resulting gelatin films were evaluated for their delayed dissolution properties. Dissolution testing was performed by monitoring the amount of gelatin film dissolved as a function of time. The gelatin film was inserted into a sinker and placed in a beaker containing a stir bar and 750 ml of 0.1 M HCl solution (pH 1) for 120 minutes. Then, 250 ml of 0.2 M Na3PO4 solution was added and the pH was adjusted to 6.8. The beaker was stirred for an additional 45 minutes. The amount of gelatin in the solution was measured spectrophotometrically at 218 nm over time.

[0123] The results are shown in Table 3.

[0124] [Table 4]

[0125] The gelatin films of the examples 1 and 2 were found to be nearly intact after 120 minutes in acidic medium. After exposure to buffered medium, dissolution of samples 1 and 2 was rapid and complete. Thus, samples 1 and 2 exhibit the desired delayed release when used as capsule films.

[0126] Example 3 Experiments with 6 wt % SDS (9 wt % in the dry film) showed a clear delayed dissolution in acid with 50% dissolution in 30 minutes and 65% dissolution in 60 minutes.

[0127] Examples 4 to 6, Comparative Example A Gelatin films according to Table 4 were prepared using the same methods and evaluated using the same methods as in Example 1.

[0128] [Table 5]

[0129] The thickness dimensions of the films prepared are provided in Table 5 below.

[0130] [Table 6]

[0131] The results of investigating the delayed dissolution properties are shown in Table 6.

[0132] [Table 7]

[0133] The gelatin films 5 and 6 of the examples were found to be almost intact after 120 minutes in acidic medium. After exposure to buffered medium, the dissolution of samples 5 and 6 was rapid and complete, thus meeting the requirements for delayed release capsules. Gelatin film A dissolves easily and therefore does not exhibit delayed release properties. Gelatin film 4 shows delayed dissolution, although it may not be sufficient for complete enteric behavior, and such films could be used for capsules that show delayed sustained release in the gastrointestinal tract.

[0134] Examples 7 to 9, Comparative Example C A hard capsule film was prepared according to the process of Example 1 according to Table 7 using gelatin bloom 243 having a viscosity of 4.6 mPa s.

[0135] [Table 8]

[0136] Films were prepared with a thickness of about 0.1 mm. The delayed dissolution properties were investigated and the results are shown in Table 8.

[0137] [Table 9]

[0138] Example gelatin film 9 was found to be almost intact after 120 minutes in acidic medium. After exposure to buffered medium, dissolution of sample 9 was rapid and complete, thus meeting the requirements for use as delayed release capsules. Gelatin film C dissolves easily and therefore does not exhibit delayed release properties. Gelatin film 7 shows slightly delayed dissolution, and capsules containing said film may exhibit slightly delayed release. Gelatin film 8 shows a clear delayed release, although this may not be sufficient for a complete enteric behavior of the capsule. Films 7 and 8 can be used for delayed gradual release in the gastrointestinal tract.

[0139] These experiments demonstrate that the presence of a significant amount of surfactant is also effective in hard capsule films, providing delayed dissolution of the film.

[0140] Examples 10 to 13: Docusate sodium (DSS) Soft capsule films were prepared according to the process of Example 1 according to Table 9 using gelatin bloom 175 with a viscosity of 2.6 mPa s. Sodium docusate was used as the surfactant.

[0141] [Table 10]

[0142] Films were prepared with a thickness of about 1 mm. The delayed dissolution properties were investigated and the results are shown in Table 10.

[0143] [Table 11]

[0144] All the gelatin films showed delayed release behavior in the acid phase but quickly dissolved in the phosphate phase. The formulations are suitable for delayed release formulations.

[0145] Examples 14 and 15: Sodium stearate (SS) Soft capsule films were prepared according to the process of Example 1 according to Table 11 using gelatin bloom 175 with a viscosity of 2.6 mPa s. Sodium stearate was used as the surfactant.

[0146] [Table 12]

[0147] The results of investigating the delayed dissolution properties are shown in Table 12.

[0148] [Table 13]

[0149] The gelatin film showed delayed release behavior in the acid phase but quickly dissolved in the phosphate phase. The formulation is suitable for delayed release formulation.

[0150] Examples 16-17: Sodium stearoyl lactylate (SSL) Soft capsule films were prepared according to the process of Example 1 according to Table 13 using Type B gelatin with Bloom 150 having a viscosity of 3.6 mPa s. Sodium stearoyl lactylate was used as a surfactant. In Example 16, an ethanol:water mixture was used instead of DI water.

[0151] [Table 14]

[0152] The results of investigating the delayed dissolution properties are shown in Table 14.

[0153] [Table 15]

[0154] The gelatin film showed delayed release behavior in the acid phase but quickly dissolved in the phosphate phase. The formulation is suitable for delayed release formulations. Example 17 had high dissolution at the 120 minute mark, but 62% at the 60 minute mark indicates delayed dissolution.

[0155] Examples 18 to 22: Diacetyltartaric acid esters of mono- and diglycerides (DATEM) Soft capsule films were prepared according to the process of Example 1 according to Table 15. For Examples 19 and 21, Type B gelatin with Bloom 150, having a viscosity of 3.6 mPa s, was used. For Examples 18, 20 and 22, Type A gelatin with Bloom 175, having a viscosity of 2.6 mPa s, was used. A mixture of diacetyl tartaric acid esters of mono- and diglycerides (DATEM) was used as the surfactant. DATEM was commercially obtained from DynaTar.

[0156] [Table 16]

[0157] The results of investigating the delayed dissolution properties are shown in Table 16.

[0158] [Table 17]

[0159] The gelatin film exhibited delayed release behavior in the acid phase but quickly dissolved in the phosphate phase. The formulation is suitable for delayed release formulations. Examples 18-20 had high dissolution at the 120 minute mark, but less than 60% dissolution at the 60 minute mark indicates that dissolution was delayed.

Claims

1. A composition comprising gelatin and a surfactant, wherein the dissolution rate of the solid composition in an aqueous medium at pH 6.8 is higher than the dissolution rate in an aqueous medium at pH 1.

2. The composition of claim 1 , wherein the composition is a film.

3. the dissolution rate is such that no more than 80% of the composition or film dissolves within 60 minutes at 37° C. and a pH of about 1, and preferably no more than 80% of the composition or film dissolves within 120 minutes at 37° C. and a pH of about 1; More preferably, the dissolution rate is (i) 50% or less of the composition or film dissolves within 120 minutes at 37° C. and a pH of about 1; (ii) The composition or film of claim 1 or 2, wherein 50% or more of the composition or film is such that it dissolves within 45 minutes at pH 6.8 and 37°C.

4. The composition or film of any one of claims 1 to 3, wherein the surfactant comprises an anionic surfactant, a cationic surfactant, a nonionic surfactant, and an amphoteric surfactant.

5. The composition or film is 8 ~C 24 The composition or film according to any one of claims 1 to 4, comprising an anionic surfactant having an alkyl chain in an amount of about 30% by weight or more and 80% by weight or less, and gelatin in an amount of about 8% by weight or more, preferably about 10% by weight or more, based on the dry weight of the anionic surfactant.

6. 6. The composition or film of any one of claims 1 to 5, wherein the anionic surfactant comprises an anionic group and an alkyl chain moiety, the anionic group being a sulfate group, a sulfone group, a phosphate group, a phosphonate group, or a carboxylate group, preferably the anionic group is a strong acid group such as a sulfate group or a sulfonic acid group.

7. 7. A composition or film according to any one of claims 1 to 6, wherein the surfactant comprises an ether or ester group, preferably the surfactant is a non-ionic surfactant comprising an ester group, more preferably the surfactant comprises diacetyl tartaric acid esters of mono- and diglycerides.

8. The composition or film according to any one of claims 1 to 7, wherein the molecular weight of the surfactant is from about 250 g / mol to about 600 g / mol, preferably from about 300 g / mol to about 400 g / mol.

9. The composition or film according to any one of claims 1 to 8, wherein the anionic surfactant is selected from the group consisting of sodium lauryl sulfate (SLS), sodium lauryl ether sulfate, ammonium lauryl sulfate, ammonium lauryl ether sulfate, sodium stearate, magnesium stearate, calcium stearate, sodium stearyl fumarate, calcium stearyl fumarate, sodium stearoyl-2-lactylate, calcium stearoyl-2-lactylate, dioctyl sodium sulfosuccinate (sodium docusate), and sodium cetearyl sulfate, preferably selected from the group consisting of sodium lauryl sulfate (SLS), sodium lauryl ether sulfate, dioctyl sodium sulfosuccinate, and sodium stearoyl-2-lactylate, more preferably selected from the group consisting of sodium lauryl sulfate (SLS), dioctyl sodium sulfosuccinate, and sodium stearoyl-2-lactylate.

10. 10. A composition or film according to any one of claims 1 to 9, wherein the amount of surfactant is at least 8% by weight, preferably at least 10% by weight, and at most 30% by weight, preferably at most 20% by weight.

11. 11. The composition or film of any one of claims 1 to 10, wherein the composition or film further comprises at least one plasticizer selected from the group consisting of glycerol, propylene glycol, polyethylene glycol, sugar alcohols having 3 to 6 carbon atoms, organic esters such as triethyl citrate and diethyl phthalate, and combinations thereof, preferably the plasticizer is selected from the group consisting of glycerol, sorbitol, propylene glycol, or combinations thereof, more preferably the plasticizer comprises glycerol.

12. 12. The composition or film of any one of claims 1 to 11, wherein the composition or film comprises at least one plasticizer, the weight of the plasticizer being from about 10 to about 40% by weight, preferably from about 15 to about 30% by weight, on a dry weight basis.

13. A capsule, said capsule being a hard capsule comprising a capsule shell, said capsule shell comprising, preferably consisting of, the film according to any one of claims 2 to 10; or 13. The capsule, wherein the capsule is a soft capsule comprising a capsule shell, the capsule shell comprising, preferably consisting of, the film according to any one of claims 2 to 12.

14. The capsule of claim 13, wherein the film of any one of claims 2 to 13 encapsulates a fill material comprising a dietary supplement or an active pharmaceutical ingredient.

15. The capsule according to claim 13 or 14, wherein the film according to any one of claims 2 to 13 is an outer layer of the capsule.

Citation Information

Patent Citations

  • Enteric-coated gelatine empty capsules and preparation method thereof

    CN104434870A

  • Coating composition for soft capsule

    JP1988280017A

  • Rigid gelatin capsule having increased lubricity by decreasing static electricity of its coated film

    JP2002167444A

  • Gelatin hard capsule having enhanced film strength

    JP2006232798A